Back to top
more

AbCellera Biologics (ABCL)

(Delayed Data from NSDQ)

$3.01 USD

3.01
885,007

+0.04 (1.35%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $3.01 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ABCL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for AbCellera Biologics Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 786 911 748 594 8
Receivables 31 39 161 213 3
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 56 75 21 6 2
Total Current Assets 872 1,025 930 813 13
Net Property & Equipment 288 217 112 18 8
Investments & Advances 66 73 50 19 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 168 179 196 147 0
Deposits & Other Assets 94 46 31 8 2
Total Assets 1,488 1,541 1,319 1,006 23
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 50 33 32 20 3
Current Portion Long-Term Debt 0 0 0 0 2
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 19 23 27 0
Income Taxes Payable 0 0 36 36 0
Other Current Liabilities 69 66 30 20 3
Total Current Liabilities 119 118 121 103 8
Mortgages 0 0 0 0 0
Deferred Taxes/Income 135 94 98 52 1
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 2 1
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 11 19 38 14 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 336 308 293 175 13
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 8
Common Stock (Par) 753 734 722 710 5
Capital Surplus 121 74 35 6 2
Retained Earnings 280 426 268 114 -5
Other Equity -2 -1 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,152 1,233 1,026 831 10
Total Liabilities & Shareholder's Equity 1,488 1,541 1,319 1,006 23
Total Common Equity 1,152 1,233 1,026 831 3
Shares Outstanding 290.10 286.10 281.50 265.50 NA
Book Value Per Share 3.97 4.31 3.64 3.13 0.00

Fiscal Year End for AbCellera Biologics Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 723 786 811 821
Receivables NA 34 31 37 46
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 57 56 71 64
Total Current Assets NA 814 872 920 931
Net Property & Equipment NA 306 288 277 260
Investments & Advances NA 72 66 63 59
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 167 168 172 175
Deposits & Other Assets NA 105 94 81 113
Total Assets NA 1,463 1,488 1,512 1,537
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 43 50 36 52
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 3 3
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 62 69 71 63
Total Current Liabilities NA 105 119 110 119
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 149 135 134 137
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 11 10 8
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 333 336 329 342
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 765 753 748 745
Capital Surplus NA 128 121 109 96
Retained Earnings NA 239 280 327 356
Other Equity NA -2 -2 -1 -2
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 1,130 1,152 1,183 1,195
Total Liabilities & Shareholder's Equity NA 1,463 1,488 1,512 1,537
Total Common Equity 0 1,130 1,152 1,183 1,195
Shares Outstanding 294.00 293.90 290.10 290.10 288.70
Book Value Per Share 0.00 3.84 3.97 4.08 4.14